A comparison of iodine-based oral contrast agents suggests that patients like the taste of iohexol better than diatrizoate, a preference that may be useful for very ill patients who have trouble tolerating the taste of contrast agents.
Researchers from the Mallinckrodt Institute of Radiology at Washington University School of Medicine in St. Louis and the Penn State Milton S. Hershey Medical Center in Hershey, PA, studied patient reaction to taking iohexol (Omnipaque, GE Healthcare, Chalfont St. Giles, U.K.) or meglumine sodium diatrizoate (Gastroview, Covidien, Dublin, Ireland).
The researchers concluded that there was no statistically significant difference between the two agents in the incidence of adverse reactions. The extent and density of gastrointestinal tract opacification also were similar between the two groups, and the cost of the two agents is comparable given the current low cost of low-osmolar contrast agents.
The study was presented last month at the Abdominal Radiology Course meeting held by the Society of Gastrointestinal Radiologists (SGR) and the Society of Uroradiology (SUR) in Orlando, FL.
Related Reading
GE shows new eHealth technology at HIMSS, March 2, 2010
GE launches clinical knowledge platform, March 2, 2010
GE settles with Omniscan critic, February 26, 2010
GE, Intel to study home monitoring, February 24, 2010
GE's Vscan to be used at Olympics, February 19, 2010
Copyright © 2010 AuntMinnie.com
